CEGE begins Phase II GVAX trial

Cell Genesys (CEGE) began a U.S. Phase II trial of its GVAX non-patient specific cancer vaccine with cells engineered to secrete GM-CSF in up to 60 patients with pancreatic cancer undergoing surgical ...